iBio, Inc. (NYSE AMEX: IBIO) today announced that members of the Company’s senior management will present at the Wells Fargo Securities Healthcare Conference on Thursday, June 23rd, at 11:15 a.m. ET. The conference will be held at the InterContinental Hotel, Boston, MA. Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company’s web site at: www.ibioinc.com. This presentation will be archived on the Company’s web site for thirty days. About iBio, Inc. iBio develops and sells product applications of its iBioLaunch™ platform, offering collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; applicability to all biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; rapid development and validation (months versus years) of modular, scalable, and optionally robotic, multi-product manufacturing facilities with production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com. Forward-Looking Statements Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.